[Federal Register Volume 81, Number 96 (Wednesday, May 18, 2016)]
[Notices]
[Pages 31254-31255]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-11638]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-890]


Certain Sleep-Disordered Breathing Treatment Systems and 
Components Thereof; Commission's Determination To Suspend Remedial 
Orders Issued in This Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined to suspend the limited exclusion order and 
cease and desist orders issued in this investigation pending remand 
proceedings.

FOR FURTHER INFORMATION CONTACT: Panyin A. Hughes, Office of the 
General Counsel, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, telephone (202) 205-3042. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW., Washington, DC 20436, 
telephone (202) 205-2000. General information concerning the Commission 
may also be obtained by accessing its Internet server (http://www.usitc.gov). The public record for this investigation may be viewed 
on the Commission's electronic docket (EDIS) at http://edis.usitc.gov. 
Hearing-impaired persons are advised that information on this matter 
can be obtained by contacting the Commission's TDD terminal on (202) 
205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on August 23, 2013, based on a complaint filed by ResMed Corporation of 
San Diego, California; ResMed Incorporated of San Diego, California; 
and ResMed Limited of New South Wales, Australia (collectively, 
``ResMed''). 78 FR 52564 (Aug. 23, 2013). The complaint alleged 
violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in 
the importation into the United States, the sale for importation, and 
the sale within the

[[Page 31255]]

United States after importation of certain sleep-disordered breathing 
treatment systems and components thereof that infringe one or more of 
claims 32-37, 53, 79, 80, and 88 of U.S. Patent No. 7,997,267 (``the 
'267 patent''); claims 1-7 of U.S. Patent No. 7,614,398 (``the '398 
patent''); claim 1 of U.S. Patent No. 7,938,116 (``the '116 patent''); 
claims 30, 37, and 38 of U.S. Patent No. 7,341,060 (the '060 patent); 
claims 1, 3, 5, 11, 28, 30, 31, and 56 of U.S. Patent No. 8,312,883 
(``the '883 patent''); claims 1, 3, 6, 7, 9, 29, 32, 35, 40, 42, 45, 
50, 51, 56, 59, 89, 92, 94, and 96 of U.S. Patent No. 7,178,527 (the 
'527 patent); claims 19-24, 26, 29-36, and 39-41 of U.S. Patent No. 
7,950,392 (the '392 patent); and claims 13, 15, 16, 26-28, 51, 52, and 
55 of U.S. Patent No 7,926,487 (``the '487 patent''). The notice of 
investigation named the following respondents: BMC Medical Co., Ltd. of 
Beijing, China; 3B Medical, Inc. of Lake Wales, Florida; and 3B 
Products, L.L.C., of Lake Wales, Florida (collectively ``BMC''). The 
Office of Unfair Import Investigations (``OUII'') participated in the 
investigation.
    On January 9, 2014, the Administrative Law Judge (``ALJ'') issued 
an initial determination (``ID'') granting a motion by ResMed to amend 
the complaint and notice of investigation to substitute U.S. Patent No. 
RE 44,453 (``the '453 patent'') for the '398 patent and to terminate 
the investigation as to the '398 patent. See Order No. 7 (Jan. 9, 
2014). The Commission determined not to review the ID. See Commission 
Notice of Non-Review (Feb. 10, 2014); 79 FR 9000-01 (Feb. 14, 2014).
    On February 24, 2014, the ALJ issued an ID granting a motion by 
ResMed to withdraw its allegations with respect to the '116 patent. See 
Order No. 11 (Feb. 24, 2014). The Commission determined not to review 
the ID. See Commission Notice of Non-Review (March 11, 2014). On March 
18, 2014, the ALJ granted a motion by ResMed to terminate the 
investigation as to claims 26-28 of the '487 Patent. See Order No. 20 
(Mar 18, 2012). The Commission determined not to review the ID. See 
Commission Notice of Non-Review (Apr. 29, 2014).
    On August 21, 2014, the ALJ issued his final ID, finding a 
violation of section 337 by BMC with respect to certain asserted claims 
of the '392, '267, '060, '883, '527, and '453 patents. The ALJ found no 
violation of section 337 with respect to the asserted claims of the 
'487 patent.
    On September 3, 2014, the parties filed petitions for review of the 
ID. On September 11, 2014, the parties filed responses to the petitions 
for review.
    On October 16, 2014, the Commission determined to review the final 
ID in part. 79 FR 63163-65 (Oct. 22, 2014). On review, the Commission 
determined to affirm the ALJ's finding of violation of section 337. The 
Commission, however, found the '453 patent invalid for anticipation. 
Having found a violation of section 337, the Commission determined that 
the appropriate form of relief was (1) a limited exclusion order 
prohibiting the unlicensed entry of sleep-disordered breathing 
treatment systems and components thereof that infringe one or more of 
claims 1, 9, 32, 89, and 92 of the '527 patent; claims 19, 21, 29, 32, 
and 36 of the '392 patent; claims 32, 33, 34, and 53 of the '267 
patent; claims 30, 37, and 38 of the '060 patent; and claims 1, 3, 5, 
11, 28, 30, 31, and 56 of the '883 patent that are manufactured by, or 
on behalf of, or are imported by or on behalf of BMC Medical Co., Ltd., 
3B Medical, Inc., or 3B Products L.L.C. or any of their affiliated 
companies, parents, subsidiaries, agents, or other related business 
entities, or their successors or assigns, except for service and 
replacement parts for customers that purchased their covered products 
prior to the date the exclusion order becomes final; and (2) cease and 
desist orders prohibiting domestic respondents BMC Medical Co., Ltd., 
3B Medical, Inc. from conducting any of the following activities in the 
United States: Importing, selling, marketing, advertising, 
distributing, transferring (except for exportation), and soliciting 
U.S. agents or distributors for, sleep-disordered breathing treatment 
systems and components thereof covered by claims 1, 9, 32, 89, and 92 
of the '527 patent; claims 19, 21, 29, 32, and 36 of the '392 patent; 
claims 32, 33, 34, and 53 of the '267 patent; claims 30, 37, and 38 of 
the '060 patent; and claims 1, 3, 5, 11, 28, 30, 31, and 56 of the '883 
patent.
    On February 18, 2015, ResMed filed a notice of appeal in the U.S. 
Court of Appeals for the Federal Circuit, seeking review of the 
Commission's determination as to the '453 patent (Appeal No. 2015-
1360). On April 14, 2015, BMC filed a notice of appeal in the Federal 
Circuit, seeking review of the Commission's domestic industry 
determination as well as the Commission's finding that prior art does 
not render the asserted claims of the '267 patent invalid for 
obviousness (Appeal No. 2015-1576). The Court consolidated the two 
appeals on April 23, 2015.
    On March 16, 2016, the parties jointly moved to dismiss ResMed's 
appeal as to the '453 patent. On March 17, 2016, the Commission moved 
to remand BMC's appeal in light of intervening domestic industry 
precedent in Lelo Inc. v. International Trade Commisson, 789 F.3d 879 
(Fed. Cir. 2015). On March 29, 2016, the Court granted the motion 
dismiss ResMed's appeal. On April 22, 2016, the Court granted the 
Commission's remand motion, noting the Commission's indication that it 
would suspend its remedial orders as it conducts its remand 
proceedings.
    The Commission has determined to suspend the remedial orders issued 
in this investigation pending the outcome of the remand.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

    Issued: May 12, 2016.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2016-11638 Filed 5-17-16; 8:45 am]
 BILLING CODE 7020-02-P